GAMMA Investing LLC Boosts Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

GAMMA Investing LLC lifted its position in shares of Immunocore Holdings plc (NASDAQ:IMCR) by 3,318.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 19,107 shares of the company’s stock after purchasing an additional 18,548 shares during the period. GAMMA Investing LLC’s holdings in Immunocore were worth $5,670,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. GF Fund Management CO. LTD. bought a new position in Immunocore in the fourth quarter worth about $25,000. NEOS Investment Management LLC increased its position in shares of Immunocore by 10.9% during the fourth quarter. NEOS Investment Management LLC now owns 11,194 shares of the company’s stock valued at $330,000 after acquiring an additional 1,102 shares in the last quarter. Tema Etfs LLC purchased a new stake in Immunocore in the fourth quarter worth approximately $330,000. Virtus ETF Advisers LLC boosted its holdings in Immunocore by 39.0% in the fourth quarter. Virtus ETF Advisers LLC now owns 11,536 shares of the company’s stock worth $340,000 after purchasing an additional 3,238 shares during the last quarter. Finally, XTX Topco Ltd boosted its stake in shares of Immunocore by 22.2% during the 4th quarter. XTX Topco Ltd now owns 18,896 shares of the company’s stock worth $557,000 after acquiring an additional 3,437 shares during the last quarter. 84.50% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on IMCR. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price target on shares of Immunocore in a research note on Friday, March 7th. Deutsche Bank Aktiengesellschaft began coverage on shares of Immunocore in a report on Tuesday, May 27th. They issued a “buy” rating and a $65.00 price target on the stock. JPMorgan Chase & Co. reduced their target price on shares of Immunocore from $54.00 to $50.00 and set an “overweight” rating on the stock in a report on Monday, April 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $71.00 price target on shares of Immunocore in a research note on Thursday, April 10th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $100.00 price target on shares of Immunocore in a research note on Monday, June 2nd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $58.89.

Immunocore Price Performance

Shares of IMCR opened at $36.07 on Tuesday. The company has a 50 day moving average price of $30.36 and a 200-day moving average price of $30.19. Immunocore Holdings plc has a fifty-two week low of $23.15 and a fifty-two week high of $42.09. The stock has a market capitalization of $1.81 billion, a PE ratio of -37.97 and a beta of 0.83. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Immunocore (NASDAQ:IMCR) last posted its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.45. The firm had revenue of $125.13 million during the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. Immunocore’s revenue was up 33.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.49) EPS. Equities analysts predict that Immunocore Holdings plc will post -0.94 earnings per share for the current fiscal year.

Insider Buying and Selling at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares of the company’s stock, valued at approximately $63,721,463.20. The trade was a 60.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. 10.40% of the stock is currently owned by company insiders.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.